Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCAPE-PD: Spironolactone add-on to losartan in CAPD
NCT03953950Phase 4Unknown
- Sponsor
- Chiang Mai University
- Start
- Oct 2019
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in end stage renal disease (ESRD), sponsored by Chiang Mai University. Primary endpoints: Peritoneal dialysate effluent cancer antigen-125 at 6 months and Peritoneal equilibration test indices at 6 months. Status: unknown.
02
Drugs
spironolactone
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03953950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03953950.